Gilead Sciences, Inc. (LON:0QYQ)

London flag London · Delayed Price · Currency is GBP · Price in USD
140.61
+3.64 (2.66%)
At close: Jan 27, 2026
47.35%
Market Cap125.85B
Revenue (ttm)21.64B +2.8%
Net Income6.03B +6,336.5%
EPS4.78 +6,514.1%
Shares Outn/a
PE Ratio20.86
Forward PE16.32
Dividend2.36 (1.68%)
Ex-Dividend DateDec 15, 2025
Volume6,048
Average Volume4,909
Open137.60
Previous Close136.97
Day's Range137.10 - 141.52
52-Week Range92.42 - 141.52
Beta0.35
RSI76.52
Earnings DateFeb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 17,600
Stock Exchange London Stock Exchange
Ticker Symbol 0QYQ
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements